MENU
+Compare
ARDX
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$5.06
Change
-$0.66 (-11.54%)
Capitalization
1.21B

ARDX Ardelyx Forecast, Technical & Fundamental Analysis

a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases

Industry Biotechnology
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ARDX with price predictions
Feb 21, 2025

Aroon Indicator for ARDX shows an upward move is likely

ARDX's Aroon Indicator triggered a bullish signal on February 21, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 193 similar instances where the Aroon Indicator showed a similar pattern. In of the 193 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARDX moved out of overbought territory on February 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where ARDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on February 21, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARDX turned negative on February 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

ARDX moved below its 50-day moving average on February 21, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARDX broke above its upper Bollinger Band on February 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.959) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.012). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.602). ARDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.568) is also within normal values, averaging (250.738).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARDX is expected to report earnings to fall 683.50% to -11 cents per share on May 01

Ardelyx ARDX Stock Earnings Reports
Q1'25
Est.
$-0.12
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.03
The last earnings report on February 20 showed earnings per share of 1 cents, beating the estimate of 0 cents. With 6.75M shares outstanding, the current market capitalization sits at 1.21B.
A.I. Advisor
published General Information

General Information

a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Fifth Avenue
Phone
+1 510 745-1700
Employees
267
Web
https://www.ardelyx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL245.55-0.28
-0.11%
Apple
BTC.X96273.920000-303.835940
-0.31%
Bitcoin cryptocurrency
SPY599.94-10.44
-1.71%
SPDR® S&P 500® ETF Trust
GME26.42-0.62
-2.29%
GameStop Corp
TSLA337.80-16.60
-4.68%
Tesla

ARDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with RIGL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then RIGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-11.54%
RIGL - ARDX
37%
Loosely correlated
-3.55%
CSCI - ARDX
35%
Loosely correlated
-0.91%
PCVX - ARDX
34%
Loosely correlated
-3.31%
RNAC - ARDX
34%
Loosely correlated
-1.89%
XENE - ARDX
33%
Loosely correlated
+0.89%
More